Short answer
Bristol Myers Squibb (BMY) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $11.5B (up 2.6% year over year) with net income of $2.7B.
Q1 2026 key financials · XBRL
- Revenue
- $11.5B
- +2.6% YoY
- Net income
- $2.7B
- +9.0% YoY
- EPS (diluted)
- $1.31
- +9.2% YoY
Source: XBRL data from the Bristol Myers Squibb (BMY) Q1 2026 10-Q on SEC EDGAR. USD.
Bristol Myers Squibb Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11,489M, up 3% YoY from $11,201M, driven by Growth Portfolio and Eliquis demand
- GAAP EPS $1.31 vs $1.20 YoY; non-GAAP EPS $1.58 vs $1.80
- Growth Portfolio and Eliquis strongest performers; Legacy Portfolio weakened by generics and lower net prices
- Productivity initiative targeting approximately $2.0B annual savings by end of 2027
- IRA pricing pressure, Eliquis Medicaid agreement, and potential future negotiations remain key headwinds
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bristol Myers Squibb quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.